Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 11/20 | 0.48 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.37 |
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.36 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | TYK2 | P29597 | 1/20 | 0.34 |
| ▸ | KIT | P10721 | 1/20 | 0.33 |
| ▸ | FLT3 | P36888 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5889007 | 0.84 | KDR (0.70) | KDRKITFLT3 | |
| SCHEMBL5889117 | 0.77 | KDR (0.66) | KDRCHEK1KITFLT3 | |
| SCHEMBL5888998 | 0.74 | KDR (0.70) | KDRKITFLT3 | |
| SCHEMBL5889102 | 0.69 | KDR (0.66) | KDRCHEK1KIT | |
| SCHEMBL7691786 | 0.68 | KDR (0.76) | KDRKIT | |
| SCHEMBL5889043 | 0.66 | KDR (1.00) | KDRHRH4KITFLT3HRH3 | |
| SCHEMBL5889140 | 0.65 | KDR (0.80) | KDRKITFLT3 | |
| SCHEMBL5889005 | 0.64 | KDR (0.66) | KDRKIT | |
| SCHEMBL5889026 | 0.64 | KDR (0.44) | KDRKIT | |
| SCHEMBL5889223 | 0.64 | KDR (0.44) | KDRKIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020137755-A1 | Tyrosine kinase inhibitors | BILODEAU MARK T (US) | 2002-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020137755-A1 | Tyrosine kinase inhibitors | ERBB2, TYRO3, TIE1 | KDR 5/4885CHEK1 499/4885HRH4 4015/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.